2-Ethylhexanoic Acid

2-Ethylhexanoic Acid

SCHEMBL557760

CCCCC(CC)C(=O)[O-].CC[N+](C)(CC)CC

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA2 P00918 10/20 0.75
MAPK1 P28482 1/20 0.52
CA1 P00915 7/20 0.50
CYP3A4 P08684 2/20 0.47
TSHR P16473 2/20 0.47
NFKB1 P19838 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
BBOX1 O75936 1/20 0.40
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
USP2 O75604 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Ethylhexanoic Acid SCHEMBL2338859 0.91 CA2 (0.78) CA2MAPK1CA1CYP3A4TSHR
2-Ethylhexanoic Acid SCHEMBL556997 0.90 CA2 (0.84) CA2MAPK1CA1CYP3A4TSHR
Tributylmethylammonium SCHEMBL25274914 0.87 CA2 (0.72) CA2MAPK1CA1CYP3A4TSHR
2-Ethylhexanoic Acid SCHEMBL3476744 0.87 CA2 (0.78) CA2MAPK1CA1CYP3A4TSHR
2-Ethylhexanoic Acid SCHEMBL9147740 0.86 CA2 (1.00) CA2MAPK1CA1CYP3A4TSHR
2-Ethylhexanoic Acid SCHEMBL21569275 0.86 CA2 (0.91) CA2MAPK1CA1CYP3A4TSHR
2-Ethylhexanoic Acid SCHEMBL2400572 0.86 CA2 (0.91) CA2MAPK1CA1CYP3A4TSHR
2-Ethylhexanoic Acid SCHEMBL20582677 0.86 CA2 (0.91) CA2MAPK1CA1CYP3A4TSHR
2-Ethylhexanoic Acid SCHEMBL1506922 0.86 CA2 (0.91) CA2MAPK1CA1CYP3A4TSHR
2-Ethylhexanoic Acid SCHEMBL39267 0.86 CA2 (0.91) CA2MAPK1CA1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-11152432-A None JP disclosed
US-20260062548-A1 RUBBER-BONDED CELLULOSE FIBERS AND MANUFACTURING METHOD THEREFOR, RESIN COMPOSITION AND MANUFACTURING METHOD THEREFOR, AND CURABLE RESIN COMPOSITION KUREHA CORPORATION (JP) 2026-03-05 US disclosed
US-20260062512-A1 CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT KUREHA CORPORATION (JP) 2026-03-05 US disclosed
EP-4678694-A1 RESIN COMPOSITION AND METHOD FOR PRODUCING SAME, AND RESIN SHEET Ajinomoto Co., Inc. (JP) 2026-01-14 EP disclosed
US-20250382505-A1 RESIN COMPOSITION AND METHOD FOR PRODUCING SAME, AND RESIN SHEET AJINOMOTO CO., INC. (JP) 2025-12-18 US disclosed
EP-4614235-A1 ELECTROPHOTOGRAPHIC MEMBER AND ELECTROPHOTOGRAPHIC IMAGE FORMING APPARATUS CANON KABUSHIKI KAISHA (JP) 2025-09-10 EP disclosed
US-20250257162-A1 CURABLE COMPOSITION, CURED BODY, LAMINATE, OPTICAL ARTICLE, LENS, AND EYEGLASSES TOKUYAMA CORPORATION (JP) 2025-08-14 US disclosed
EP-4582463-A1 CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT Kureha Corporation (JP) 2025-07-09 EP disclosed
EP-4582459-A1 RUBBER-BONDED CELLULOSE FIBERS AND MANUFACTURING METHOD THEREFOR, RESIN COMPOSITION AND MANUFACTURING METHOD THEREFOR, AND CURABLE RESIN COMPOSITION Kureha Corporation (JP) 2025-07-09 EP disclosed
CN-119768439-A Rubber-bonded cellulose fiber, method for producing same, resin composition, method for producing same, and cured resin composition 株式会社吴羽 2025-04-04 CN disclosed
US-20150344727-A1 QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF TOSOH CORPORATION (JP) 2015-12-03 US disclosed
EP-2937369-A1 QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT, AND USE FOR SAID CATALYST Tosoh Corporation (JP) 2015-10-28 EP disclosed
EP-1669383-B1 CATALYST COMPOSITION FOR PRODUCTION OF RIGID POLYURETHANE FOAM AND ISOCYANURATE-MODIFIED RIGID POLYURETHANE FOAM AND RAW-MATERIAL COMPOSITION CONTAINING THE SAME TOSOH CORP (JP) 2014-11-12 EP disclosed
US-8877825-B2 Catalyst composition for production of polyurethane resin and method for producing polyurethane resin TOSOH CORPORATION (JP) 2014-11-04 US disclosed
US-8779018-B2 Catalyst composition for production of rigid polyurethane foam and isocyanurate-modified rigid polyurethane foam and raw-material composition containing the same TOSOH CORPORATION (JP) 2014-07-15 US disclosed
US-20120035289-A1 CATALYST COMPOSITION FOR PRODUCTION OF RIGID POLYURETHANE FOAM AND ISOCYANURATE-MODIFIED RIGID POLYURETHANE FOAM AND RAW-MATERIAL COMPOSITION CONTAINING THE SAME TOSOH CORPORATION (JP) 2012-02-09 US disclosed
US-20100130629-A1 CATALYST COMPOSITION FOR PRODUCTION OF POLYURETHANE RESIN AND METHOD FOR PRODUCING POLYURETHANE RESIN (AS AMENDED) TOSOH CORPORATION (JP) 2010-05-27 US disclosed
US-20070112085-A1 Catalyst composition for production of rigid polyurethane foam and isocyanurate-modified rigid polysurethane foam and raw-material composition containing the same TOSOH CORPORATION (JP) 2007-05-17 US disclosed
US-20070043132-A1 Catalyst and process for producing a rigid polyurethane foam TOSOH CORPORATION (JP) 2007-02-22 US disclosed
EP-1669383-A1 CATALYST COMPOSITION FOR PRODUCTION OF RIGID POLYURETHANE FOAM AND ISOCYANURATE-MODIFIED RIGID POLYURETHANE FOAM AND RAW-MATERIAL COMPOSITION CONTAINING THE SAME Tosoh Corporation (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062548-A1 RUBBER-BONDED CELLULOSE FIBERS AND MANUFACTURING METHOD THEREFOR, RESIN COMPOSITION AND MANUFACTURING METHOD THEREFOR, AND CURABLE RESIN COMPOSITION CROCC, WASF2, DCXR CA2 4353/4885MAPK1 2443/4885CA1 3940/4885
US-20150344727-A1 QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF CA2, KCNMB1, BET1 CA2 1/4885MAPK1 734/4885CA1 8/4885
US-20260062512-A1 CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT EHMT1, EHMT2, ASH2L CA2 219/4885MAPK1 2597/4885CA1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.